BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
BioLineRx to Present at the 2020 Biotech Showcase
Shareholders Meeting
Oppenheimer 30th Annual Healthcare Conference